A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results